Compare VYGR & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | JELD |
|---|---|---|
| Founded | 2013 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 190.5M |
| IPO Year | 2015 | 2017 |
| Metric | VYGR | JELD |
|---|---|---|
| Price | $4.00 | $2.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $17.00 | $4.23 |
| AVG Volume (30 Days) | 467.1K | ★ 1.6M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,316,000.00 | ★ $3,304,951,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.65 | $1.70 |
| 52 Week High | $6.37 | $10.09 |
| Indicator | VYGR | JELD |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 48.02 |
| Support Level | $4.24 | $2.66 |
| Resistance Level | $4.58 | $3.00 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 31.36 | 50.05 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.